|
LIVE WEBINAR: Thursday, January 11, 2024, 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Join us on Thursday, January 11th for this CME/MOC-accredited webinar Faculty
Stephanie L Graff, MD, FACP Associate Professor of Medicine Warren Alpert Medical School of Brown University Director of Breast Oncology Lifespan Cancer Institute Co-Lead, Breast Cancer Translational Disease Research Group Legorreta Cancer Center at Brown University Medical Advisor, Dr Susan Love Foundation for Breast Cancer Research Providence, Rhode Island Erica Mayer, MD, MPH, FASCO Director of Breast Cancer Clinical Research Breast Oncology Center Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts
Moderator
Neil Love, MD Research To Practice Miami, Florida Thursday, January 11, 2024 Topics to Be Discussed
Target Audience Learning Objectives
CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Graff — Advisory Boards (All Relationships Ended, Self): AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Pfizer Inc, Seagen Inc, Stemline Therapeutics Inc; Research Funding (All Funds to Institution): AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis; Nonrelevant Financial Relationship: HCA Healthcare (stock ownership). Dr Mayer — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |